To evaluate the safety and efficacy of OTEZLA in actual clinical settings of use in patients with Psoriasis vulgaris that is with an inadequate response to topical therapies and Psoriasis arthropathica 1. Planned registration period 2 years 2. Planned surveillance period for 4 years from 6 months after launch
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Adverse Events (AEs)
Timeframe: Up to approximately 12 months
General Improvement Rating
Timeframe: Approximately 1 year from administration
General health assessment on VAS
Timeframe: Approximately 1 year from administration
Changes in physician general assessment
Timeframe: Approximately 1 year from administration
Percentage of patients with Dermatology Life Quality Index (DLQI)
Timeframe: Approximately 1 year from administration
Change from baseline activity for arthritis
Timeframe: Approximately 1 year from administration